EMC Capital Management Purchases 946 Shares of Moderna, Inc. (NASDAQ:MRNA)

EMC Capital Management raised its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 311.2% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,250 shares of the company’s stock after purchasing an additional 946 shares during the quarter. EMC Capital Management’s holdings in Moderna were worth $52,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. State Street Corp increased its holdings in Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after purchasing an additional 1,823,276 shares during the period. Geode Capital Management LLC increased its stake in shares of Moderna by 2.6% during the third quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock valued at $470,670,000 after buying an additional 178,115 shares during the period. Wellington Management Group LLP raised its holdings in shares of Moderna by 21.0% during the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after acquiring an additional 906,114 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Moderna by 0.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock worth $260,023,000 after acquiring an additional 19,819 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its holdings in Moderna by 6.2% in the third quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock valued at $205,431,000 after acquiring an additional 178,939 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

MRNA has been the topic of a number of research reports. Evercore ISI cut their target price on shares of Moderna from $60.00 to $50.00 and set an “in-line” rating on the stock in a research note on Monday, January 27th. JPMorgan Chase & Co. cut their price objective on Moderna from $59.00 to $45.00 and set an “underweight” rating on the stock in a research report on Tuesday, November 26th. Wolfe Research initiated coverage on Moderna in a research note on Friday, November 15th. They issued an “underperform” rating and a $40.00 target price for the company. Bank of America reaffirmed an “underperform” rating and issued a $41.00 price target on shares of Moderna in a research note on Tuesday, December 10th. Finally, Sanford C. Bernstein started coverage on shares of Moderna in a report on Thursday, October 17th. They set a “market perform” rating and a $55.00 target price on the stock. Four analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $67.26.

Moderna Stock Down 3.9 %

MRNA opened at $39.42 on Friday. The stock has a market capitalization of $15.17 billion, a price-to-earnings ratio of -6.77 and a beta of 1.60. The firm has a 50 day moving average price of $40.89 and a 200-day moving average price of $61.32. Moderna, Inc. has a twelve month low of $31.94 and a twelve month high of $170.47. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. During the same period last year, the business posted ($1.39) EPS. The company’s revenue for the quarter was up 3.8% on a year-over-year basis. Equities research analysts forecast that Moderna, Inc. will post -9.26 earnings per share for the current year.

Insider Activity

In related news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the transaction, the insider now directly owns 19,717 shares in the company, valued at approximately $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 2,664 shares of company stock valued at $115,210 in the last quarter. 15.70% of the stock is currently owned by insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.